Human equilibrative nucleoside transporter 1 and Notch3 can predict gemcitabine effects in patients with unresectable pancreatic cancer

British Journal of Cancer

Volumn 108, Issue 7, 2013, Pages 1488-1494

  Eto, K ^a   Kawakami, H ^a   Kuwatani, M ^a   Kudo, T ^a   Abe, Y ^a   Kawahata, S ^a   Takasawa, A ^b   Fukuoka, M ^b   Matsuno, Y ^b   Asaka, M ^a   Sakamoto, N ^a  

^a HOKKAIDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b HOKKAIDO UNIVERSITY HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

EQUILIBRATIVE NUCLEOSIDE TRANSPORTER 1; GEMCITABINE; MESSENGER RNA; NOTCH3 RECEPTOR;

AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER SURVIVAL; COMORBIDITY; ENDOSCOPIC ULTRASOUND GUIDED FINE NEEDLE BIOPSY; FEMALE; GENE EXPRESSION; HUMAN; INOPERABLE CANCER; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PANCREAS CARCINOMA; PANCREATIC DUCTAL CARCINOMA; PREDICTION; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; THERAPY EFFECT;

ADULT; AGED; AGED, 80 AND OVER; ANTIMETABOLITES, ANTINEOPLASTIC; CARCINOMA, PANCREATIC DUCTAL; DEOXYCYTIDINE; EQUILIBRATIVE NUCLEOSIDE TRANSPORTER 1; FEMALE; HUMANS; MALE; MIDDLE AGED; PANCREATIC NEOPLASMS; RECEPTORS, NOTCH; RETROSPECTIVE STUDIES; RNA, MESSENGER;

EID: 84876481679     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2013.108     Document Type: Article

References (27)

1. Ashida R, Nakata B, Shigekawa M, Mizuno N, Sawaki A, Hirakawa K, Arakawa T, Yamao K (2009) Gemcitabine sensitivity-related mRNA expression in endoscopic ultrasound-guided fine-needle aspiration biopsy of unresectable pancreatic cancer. J Exp Clin Cancer Res 28: 83.
2. Buchholz M, Kestler HA, Bauer A, Böck W, Rau B, Leder G, Kratzer W, Bommer M, Scarpa A, Schilling MK, Adler G, Hoheisel JD, Gress TM (2005) Specialized DNA arrays for the differentiation of pancreatic tumors. Clin Cancer Res 11(22): 8048-8054. (Pubitemid 41698747)
3. Burris HA, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR, Cripps MC, Portenoy RK, Storniolo AM, Tarassoff P, Nelson R, Dorr FA, Stephens CD, Von Hoff DD (1997) Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 15(6): 2403-2413. (Pubitemid 27251144)
4. Conroy T, Desseigne F, Ychou M, Bouché O, Guimbaud R, Bécouarn Y, Adenis A, Raoul JL, Gourgou-Bourgade S, de la Fouchardière C, Bennouna J, Bachet JB, Khemissa-Akouz F, Péré-Vergé D, Delbaldo C, Assenat E, Chauffert B, Michel P, Montoto-Grillot C, Ducreux M. Groupe Tumeurs Digestives of Unicancer; PRODIGE Intergroup (2011) FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 364(19): 1817-1825.
5. Dang L, Fan X, Chaudhry A, Wang M, Gaiano N, Eberhart CG (2006) Notch3 signaling initiates choroid plexus tumor formation. Oncogene 25(3): 487-491. (Pubitemid 43117634)
6. Doucas H, Mann CD, Sutton CD, Garcea G, Neal CP, Berry DP, Manson MM (2008) Expression of nuclear Notch3 in pancreatic adenocarcinomas is associated with adverse clinical features, and correlates with the expression of STAT3 and phosphorylated Akt. J Surg Oncol 97(1): 63-68.
7. Farrell JJ, Elsaleh H, Garcia M, Lai R, Ammar A, Regine WF, Abrams R, Benson AB, Macdonald J, Cass CE, Dicker AP, Mackey JR (2009) Human equilibrative nucleoside transporter 1 levels predict response to gemcitabine in patients with pancreatic cancer. Gastroenterology 136(1): 187-195.
8. Fujita H, Ohuchida K, Mizumoto K, Egami T, Miyasaka Y, Yamaguchi H, Yu J, Cui L, Onimaru M, Takahata S, Tsuneyoshi M, Tanaka M (2008) Quantitative analysis of hTERT mRNA levels in cells microdissected from cytological specimens. Cancer Sci 99(11): 2244-2251.
9. Fujita H, Ohuchida K, Mizumoto K, Itaba S, Ito T, Nakata K, Yu J, Kayashima T, Souzaki R, Tajiri T, Manabe T, Ohtsuka T, Tanaka M (2010) Gene expression levels as predictive markers of outcome in pancreatic cancer after gemcitabine-based adjuvant chemotherapy. Neoplasia 12(10): 807-817.
10. Garcia-Manteiga J, Molina-Arcas M, Casado FJ, Mazo A, Pastor-Anglada M (2003) Nucleoside transporter profiles in human pancreatic cancer cells: role of hCNT1 in 2, 2-difluorodeoxycytidine-induced cytotoxicity. Clin Cancer Res 9(13): 5000-5008. (Pubitemid 37323307)
11. Giovannetti E, Del Tacca M, Mey V, Funel N, Nannizzi S, Ricci S, Orlandini C, Boggi U, Campani D, Del Chiaro M, Iannopollo M, Bevilacqua G, Mosca F, Danesi R (2006) Transcription analysis of human equilibrative nucleoside transporter-1 predicts survival in pancreas cancer patients treated with gemcitabine. Cancer Res 66(7): 3928-3935.
12. Itoi T, Sofuni A, Fukushima N, Itokawa F, Tsuchiya T, Kurihara T, Moriyasu F, Tsuchida A, Kasuya K (2007) Ribonucleotide reductase subunit M2 mRNA expression in pretreatment biopsies obtained from unresectable pancreatic carcinomas. J Gastroenterol 42(5): 389-394. (Pubitemid 47097256)
13. Itoi T, Takei K, Sofuni A, Itokawa F, Tsuchiya T, Kurihara T, Nakamura K, Moriyasu F, Tsuchida A, Kasuya K (2005) Immunohistochemical analysis of p53 and MIB-1 in tissue specimens obtained from endoscopic ultrasonography-guided fine needle aspiration biopsy for the diagnosis of solid pancreatic masses. Oncol Rep 13(2): 229-234.
14. Khalid A, Nodit L, Zahid M, Bauer K, Brody D, Finkelstein SD, McGrath KM (2006) Endoscopic ultrasound fine needle aspirate DNA analysis to differentiate malignant and benign pancreatic masses. Am J Gastroenterol 101(11): 2493-2500. (Pubitemid 44665243)
15. Maréchal R, Bachet JB, Mackey JR, Dalban C, Demetter P, Graham K, Couvelard A, Svrcek M, Bardier-Dupas A, Hammel P, Sauvanet A, Louvet C, Paye F, Rougier P, Penna C, André T, Dumontet C, Cass CE, Jordheim LP, Matera EL, Closset J, Salmon I, Deviere J, Emile JF, Van Laethem JL (2012) Levels of gemcitabine transport and metabolism proteins predict survival times of patients treated with gemcitabine for pancreatic adenocarcinoma. Gastroenterology 143(3): 664-674e6.
16. Maréchal R, Mackey JR, Lai R, Demetter P, Peeters M, Polus M, Cass CE, Salmon I, Deviere J, Van Laethem JL (2010) Deoxycitidine kinase is associated with prolonged survival after adjuvant gemcitabine for resected pancreatic adenocarcinoma. Cancer 116(22): 5200-5206.
17. Matsuno S, Egawa S, Fukuyama S, Motoi F, Sunamura M, Isaji S, Imaizumi T, Okada S, Kato H, Suda K, Nakao A, Hiraoka T, Hosotani R, Takeda K (2004) Pancreatic Cancer Registry in Japan: 20 years of experience. Pancreas 28(3): 219-230. (Pubitemid 38437313)
18. Nakahira S, Nakamori S, Tsujie M, Takahashi Y, Okami J, Yoshioka S, Yamasaki M, Marubashi S, Takemasa I, Miyamoto A, Takeda Y, Nagano H, Dono K, Umeshita K, Sakon M, Monden M (2007) Involvement of ribonucleotide reductase M1 subunit overexpression in gemcitabine resistance of human pancreatic cancer. Int J Cancer 120(6): 1355-1363.
19. Neoptolemos JP, Stocken DD, Friess H, Bassi C, Dunn JA, Hickey H, Beger H, Fernandez-Cruz L, Dervenis C, Lacaine F, Falconi M, Pederzoli P, Pap A, Spooner D, Kerr DJ, Büchler MW. Cancer ESGfP (2004) A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N Engl J Med 350(12): 1200-1210. (Pubitemid 38339364)
20. Oettle H, Post S, Neuhaus P, Gellert K, Langrehr J, Ridwelski K, Schramm H, Fahlke J, Zuelke C, Burkart C, Gutberlet K, Kettner E, Schmalenberg H, Weigang-Koehler K, Bechstein WO, Niedergethmann M, Schmidt-Wolf I, Roll L, Doerken B, Riess H (2007) Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial. JAMA 297(3): 267-277. (Pubitemid 46143304)
21. Park JT, Chen X, Tropè CG, Davidson B, IeM Shih, Wang TL (2010) Notch3 overexpression is related to the recurrence of ovarian cancer and confers resistance to carboplatin. Am J Pathol 177(3): 1087-1094.
22. Tada M, Komatsu Y, Kawabe T, Sasahira N, Isayama H, Toda N, Shiratori Y, Omata M (2002) Quantitative analysis of K-ras gene mutation in pancreatic tissue obtained by endoscopic ultrasonography-guided fine needle aspiration: clinical utility for diagnosis of pancreatic tumor. Am J Gastroenterol 97(9): 2263-2270.
23. Takahashi K, Yamao K, Okubo K, Sawaki A, Mizuno N, Ashida R, Koshikawa T, Ueyama Y, Kasugai K, Hase S, Kakumu S (2005) Differential diagnosis of pancreatic cancer and focal pancreatitis by using EUS-guided FNA. Gastrointest Endosc 61(1): 76-79. (Pubitemid 40169815)
24. Wagner M, Redaelli C, Lietz M, Seiler CA, Friess H, Büchler MW (2004) Curative resection is the single most important factor determining outcome in patients with pancreatic adenocarcinoma. Br J Surg 91(5): 586-594. (Pubitemid 38624667)
25. Wang Z, Li Y, Kong D, Banerjee S, Ahmad A, Azmi AS, Ali S, Abbruzzese JL, Gallick GE, Sarkar FH (2009) Acquisition of epithelial-mesenchymal transition phenotype of gemcitabine-resistant pancreatic cancer cells is linked with activation of the notch signaling pathway. Cancer Res 69(6): 2400-2407.
26. Yao J, Qian C (2010) Inhibition of Notch3 enhances sensitivity to gemcitabine in pancreatic cancer through an inactivation of PI3K/Akt-dependent pathway. Med Oncol 27(3): 1017-1022.
27. Yasuda I, Goto N, Tsurumi H, Nakashima M, Doi S, Iwashita T, Kanemura N, Kasahara S, Adachi S, Hara T, Shimizu M, Takami T, Moriwaki H (2012) Endoscopic ultrasound-guided fine needle aspiration biopsy for diagnosis of lymphoproliferative disorders: feasibility of immunohistological, flow cytometric, and cytogenetic assessments. Am J Gastroenterol 107(3): 397-404.